No supporting evidence of classification based on FFPE samples, ambiguity in classification of EGFR mutants, and inclusion of bona-fide platelet genes in discriminator sets indicate no biological basis for using RNA-seq from tumor-educated platelets as a source in "liquid biopsy"
This paper critiques the use of RNA-seq from tumor-educated platelets as a liquid biopsy source, highlighting methodological flaws and lack of biological evidence.
bioRxiv · Jul 2, 2017 · PreprintCancer Biology